In the Original Investigation titled “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial” by Correll et al,¹ published online January 8, 2020, in the Efficacy subsection of the Results section, the multiplicity-adjusted P values for change from baseline to day 28 in the Positive and Negative Syndrome Scale total score vs placebo and for change from baseline to day 28 in the Clinical Global Impression–Severity of Illness were P = .04, not P = .05; this change has also been made to the corresponding data in Table 2. Furthermore, the nominal P values for these data were actually unadjusted. This article has been corrected online.

^{在 Correll 等人于 2020 年1}月 8 日在线发表的题为“Lumateperone 治疗精神分裂症的疗效和安全性：一项随机临床试验”的原始调查中， 1在结果部分的疗效小节中，多重性调整的P值阳性和阴性症状量表总分与安慰剂相比从基线到第 28 天的变化以及临床总体印象 - 疾病严重程度从基线到第 28 天的变化是P  = .04，而不是P  = .05；表 2 中的相应数据也发生了这种变化。此外，这些数据的标称P值实际上未经调整。本文已在线更正。